Cerchietti Research Lab

Publications

Found 158 results
Filters: First Letter Of Last Name is M  [Clear All Filters]
2002
Cerchietti LCA, Navigante AH, Bonomi MR, Zaderajko MA, Menéndez PR, Pogany CE, Roth BMC.  2002.  Effect of topical morphine for mucositis-associated pain following concomitant chemoradiotherapy for head and neck carcinoma.. Cancer. 95(10):2230-6.
2004
Polo JM, Dell'Oso T, Ranuncolo SMaris, Cerchietti L, Beck D, Da Silva GF, Prive GG, Licht JD, Melnick A.  2004.  Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.. Nat Med. 10(12):1329-35.
2006
Prokhortchouk A, Sansom O, Selfridge J, Caballero IM, Salozhin S, Aithozhina D, Cerchietti L, Meng FGuo, Augenlicht LH, Mariadason JM et al..  2006.  Kaiso-deficient mice show resistance to intestinal cancer.. Mol Cell Biol. 26(1):199-208.
Prokhortchouk A, Sansom O, Selfridge J, Caballero IM, Salozhin S, Aithozhina D, Cerchietti L, Meng FGuo, Augenlicht LH, Mariadason JM et al..  2006.  Kaiso-deficient mice show resistance to intestinal cancer.. Mol Cell Biol. 26(1):199-208.
Prokhortchouk A, Sansom O, Selfridge J, Caballero IM, Salozhin S, Aithozhina D, Cerchietti L, Meng FGuo, Augenlicht LH, Mariadason JM et al..  2006.  Kaiso-deficient mice show resistance to intestinal cancer.. Mol Cell Biol. 26(1):199-208.
2007
Polo JM, Juszczynski P, Monti S, Cerchietti L, Ye K, Greally JM, Shipp M, Melnick A.  2007.  Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas.. Proc Natl Acad Sci U S A. 104(9):3207-12.
Polo JM, Juszczynski P, Monti S, Cerchietti L, Ye K, Greally JM, Shipp M, Melnick A.  2007.  Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas.. Proc Natl Acad Sci U S A. 104(9):3207-12.
2008
Cerchietti LC, Polo JM, Da Silva GF, Farinha P, Shaknovich R, Gascoyne RD, Dowdy SF, Melnick A.  2008.  Sequential transcription factor targeting for diffuse large B-cell lymphomas.. Cancer Res. 68(9):3361-9.
Ghetu AF, Corcoran CM, Cerchietti L, Bardwell VJ, Melnick A, Prive GG.  2008.  Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer.. Mol Cell. 29(3):384-91.
2009
Ci W, Polo JM, Cerchietti L, Shaknovich R, Wang L, Yang SNing, Ye K, Farinha P, Horsman DE, Gascoyne RD et al..  2009.  The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.. Blood. 113(22):5536-48.
Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A, Guo Y et al..  2009.  Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models.. Proc Natl Acad Sci U S A. 106(20):8368-73.
Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A, Guo Y et al..  2009.  Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models.. Proc Natl Acad Sci U S A. 106(20):8368-73.
Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A, Guo Y et al..  2009.  Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models.. Proc Natl Acad Sci U S A. 106(20):8368-73.
Cerchietti LC, Yang SNing, Shaknovich R, Hatzi K, Polo JM, Chadburn A, Dowdy SF, Melnick A.  2009.  A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo.. Blood. 113(15):3397-405.
Cerchietti LC, Lopes EC, Yang SNing, Hatzi K, Bunting KL, Tsikitas LA, Mallik A, Robles AI, Walling J, Varticovski L et al..  2009.  A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.. Nat Med. 15(12):1369-76.
Cerchietti LC, Lopes EC, Yang SNing, Hatzi K, Bunting KL, Tsikitas LA, Mallik A, Robles AI, Walling J, Varticovski L et al..  2009.  A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.. Nat Med. 15(12):1369-76.
2010
Duy C, J Yu J, Nahar R, Swaminathan S, Kweon S-mi, Polo JM, Valls E, Klemm L, Shojaee S, Cerchietti L et al..  2010.  BCL6 is critical for the development of a diverse primary B cell repertoire.. J Exp Med. 207(6):1209-21.
Duy C, J Yu J, Nahar R, Swaminathan S, Kweon S-mi, Polo JM, Valls E, Klemm L, Shojaee S, Cerchietti L et al..  2010.  BCL6 is critical for the development of a diverse primary B cell repertoire.. J Exp Med. 207(6):1209-21.
Cerchietti LC, Hatzi K, Caldas-Lopes E, Yang SNing, Figueroa ME, Morin RD, Hirst M, Mendez L, Shaknovich R, Cole PA et al..  2010.  BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.. J Clin Invest. 120(12):4569-82.
Cerchietti LC, Hatzi K, Caldas-Lopes E, Yang SNing, Figueroa ME, Morin RD, Hirst M, Mendez L, Shaknovich R, Cole PA et al..  2010.  BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.. J Clin Invest. 120(12):4569-82.
Cerchietti LC, Hatzi K, Caldas-Lopes E, Yang SNing, Figueroa ME, Morin RD, Hirst M, Mendez L, Shaknovich R, Cole PA et al..  2010.  BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.. J Clin Invest. 120(12):4569-82.
Cerchietti LC, Hatzi K, Caldas-Lopes E, Yang SNing, Figueroa ME, Morin RD, Hirst M, Mendez L, Shaknovich R, Cole PA et al..  2010.  BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.. J Clin Invest. 120(12):4569-82.
Shaknovich R, Geng H, Johnson NA, Tsikitas L, Cerchietti L, Greally JM, Gascoyne RD, Elemento O, Melnick A.  2010.  DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma.. Blood. 116(20):e81-9.
Elstrom RL, Martin P, Ostrow K, Barrientos J, Chadburn A, Furman R, Ruan J, Shore T, Schuster M, Cerchietti L et al..  2010.  Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies.. Clin Lymphoma Myeloma Leuk. 10(3):192-6.
Elstrom RL, Martin P, Ostrow K, Barrientos J, Chadburn A, Furman R, Ruan J, Shore T, Schuster M, Cerchietti L et al..  2010.  Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies.. Clin Lymphoma Myeloma Leuk. 10(3):192-6.